Financial

News

Sarepta pulls plug on Duchenne exon-skipping drug

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

News

Nick Green, president and CEO of Avid Bioservices

Avid Bioservices to go private in $1.1bn private equity deal

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part

News

Wegovy romps ahead after key rival sees slowdown

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago.

News

UK Chancellor pledges £22bn rise in day-to-day NHS spending

In a historic moment today, Rachel Reeves became the first female UK Chancellor to deliver a Budget statement, which featured a major cash injection into the NHS.

News

Alarm bell rings for GSK as US policy dents RSV jab sales

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

News

Pfizer rebuffs Starboard criticism as it raises forecasts

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without c

Sarepta pulls plug on Duchenne exon-skipping drug

Avid Bioservices to go private in $1.1bn private equity deal

Wegovy romps ahead after key rival sees slowdown

UK Chancellor pledges £22bn rise in day-to-day NHS spending

Alarm bell rings for GSK as US policy dents RSV jab sales

Pfizer rebuffs Starboard criticism as it raises forecasts

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

Financial

Editor's Picks